CBD has minimal affinity for CB receptors. It acts being an antagonist or partial antagonist at endogenous cannabinoid receptors (equally CB1 and CB2 receptor types together with other G-protein-coupled receptors [GPCRs]) by inhibiting entire binding of immediate ligands, and could act principal